Brought to you by 
Grace, Oxford Bioscience create gene delivery JV, Geniva
24 Oct 2019
Executive Summary
WR Grace put its Auragen genetic vaccine subsidiary--the remaining assets of its former Agracetus subsidiary--into Geniva, a 50-50 joint venture with Oxford Bioscience (drug delivery devices).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Joint Venture
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Grace, Oxford Bioscience create gene delivery JV, Geniva
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice